- Home
- RGEN
RGEN
Repligen Corporation
as 04-24-2025 4:00pm EST
Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, or CDMOs, and other life science companies. It sells four main product categories: filtration (including fluid management) is the largest category and was 58% of 2024 revenue, while chromatography, proteins, and process analytics were 19%, 12%, and 9%, respectively. Customers in North America, Europe, and Asia Pacific contributed 44%, 37%, and 19% of revenue, respectively.
Upcoming Earnings Alert:
Get ready for potential market movements as Repligen Corporation RGEN prepares to release earnings report on 29 Apr 2025.
| Founded: | 1981 | Country: | United States |
| Employees: | N/A | City: | WALTHAM |
| Market Cap: | 7.1B | IPO Year: | N/A |
| Target Price: | $175.56 | AVG Volume (30 days): | 953.7K |
| Analyst Decision: | Buy | Number of Analysts: | 12 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.46 | EPS Growth: | N/A |
| 52 Week Low/High: | $102.97 - $182.52 | Next Earning Date: | 04-29-2025 |
| Revenue: | $634,439,000 | Revenue Growth: | 0.33% |
| Revenue Growth (this year): | 12.29% | Revenue Growth (next year): | 15.20% |
Stock Insider Trading Activity of Repligen Corporation (RGEN)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Pax Margaret | RGEN | Director | Mar 17 '25 | Buy | $150.69 | 250 | $37,672.50 | 1,043 | |
| Hunt Anthony | RGEN | Director | Mar 17 '25 | Sell | $151.33 | 26,756 | $4,080,663.26 | 162,897 |
Latest Repligen Corporation News
RGEN Breaking Stock News: Dive into RGEN Ticker-Specific Updates for Smart Investing
Zacks
a day ago
Will Repligen (RGEN) Beat Estimates Again in Its Next Earnings Report?
Zacks
a day ago
Earnings Preview: Guardant Health (GH) Q1 Earnings Expected to Decline
Argus Research
2 days ago
RGEN: Rating decreased to a SELL
Zacks
2 days ago
Repligen (RGEN) Reports Next Week: Wall Street Expects Earnings Growth
Simply Wall St.
7 days ago
Three Stocks That May Be Undervalued In April 2025
Zacks
8 days ago
GMAB or RGEN: Which Is the Better Value Stock Right Now?
Argus Research
9 days ago
RGEN: Raising target price to $133.00
GlobeNewswire
9 days ago
Repligen to Report First Quarter 2025 Financial Results
Compare RGEN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "RGEN Repligen Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.